Form 4: Monte Rosa Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Jan Skvarka acquired 22,100 stock options in Monte Rosa Therapeutics, Inc. on June 12, 2024.
Summary
- Jan Skvarka, a director of Monte Rosa Therapeutics, Inc. (GLUE), acquired 22,100 stock options on June 12, 2024.
- The exercise price of these options is $4.16.
- The options vest fully on the earlier of June 12, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
- The expiration date for these options is June 12, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director aligns their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of transaction: Jan Skvarka acquired 22,100 stock options. |
| 06/12/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/13/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.